Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis.
Eleanor L WattsAurora Perez-CornagoGeorgina K FensomKarl Smith-ByrneUrwah NoorColm D AndrewsMarc J GunterMichael V HolmesRichard M MartinKonstantinos K TsilidisDemetrius AlbanesAurelio BarricarteH Bas Bueno-de-MesquitaBarbara A CohnMelanie Deschasaux-TanguyNiki L DimouLuigi FerrucciLeon FlickerNeal D FreedmanGraham G GilesEdward L GiovannucciChristopher A HaimanGraham J HankeyJeffrey M P HollyJiaqi HuangWen-Yi HuangLauren M HurwitzRudolf KaaksTatsuhiko KuboLoic Le MarchandRobert J MacInnisSatu MännistöE Jeffrey MetterKazuya MikamiLorelei A MucciAnja W OlsenKotaro OzasaDomenico PalliKathryn L PenneyElizabeth A PlatzMichael N PollakMonique J RoobolCatherine A SchaeferJeannette M SchenkPär StattinAkiko TamakoshiElin ThysellChiaojung Jillian TsaiMathilde TouvierStephen K Van Den EedenElisabete WeiderpassStephanie J WeinsteinLynne R WilkensBu B Yeapnull nullNaomi E AllenTimothy J KeyRuth C TravisPublished in: International journal of epidemiology (2022)
These findings support the role of IGF-I in the development of prostate cancer, including for aggressive disease.